Reimold 1993.

Methods	RCT Open‐label Loss to follow‐up reported: yes
Participants	Any symptomatic AF or AFl. Type: paroxysmal 47%, persistent 53% (mean duration: 36 months). n = 100 Men: 64% Age (mean): 61 (SD 12) years Structural heart disease: 81%. LAD: 46 mm. LVEF: 59%
Interventions	Propafenone 675 mg/day vs sotalol 320 mg/day Method of AF cardioversion: both pharmacological and electrical, % NS Warfarin discretionary
Outcomes	At 12 months: Mortality Proarrhythmia Adverse effects AF recurrence
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation stratification scheme using a permuted blocks design generated before initiation of the trial.
Allocation concealment (selection bias)	Low risk	Drug assignment provided in sealed envelopes by a research pharmacist.
Blinding (performance bias and detection bias) All outcomes	High risk	Not described as a blind study.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Participants lost to follow‐up were not clearly detailed but seemed to be few. Analysis was intention‐to‐treat.
Selective reporting (reporting bias)	Low risk	All prespecified outcomes and expected outcomes were well reported.
Other bias	Low risk	No other bias apparent.